Format

Send to

Choose Destination
Cancer Invest. 2009 Jun;27(5):549-60. doi: 10.1080/07357900802620794.

Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.

Author information

1
Department of Urology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA.

Abstract

To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology. Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer. Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.

PMID:
19229700
PMCID:
PMC2693083
DOI:
10.1080/07357900802620794
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center